Journal of Industrial and Engineering Chemistry, Vol.9, No.6, 640-646, November, 2003
Cytotoxicity Mediated by Deuterium Oxide in Urological Cancer Cells
E-mail:
Deuterium oxide (D2O, heavy water) is a moderator in nuclear reactors and has the cytotoxic effects oil various cancer cells, depending on their origin. We Studied the cytotoxic effects of the morphological changes and proliferation patterns for the urological cancer cells lines, the renal cancer cell lines A-498, the prostate cancer cell lines DU-145, and the bladder cancer cell lines T-24, mediated with 25 and 50% D2O mixtures in pure water. These were studied with different concentrations of D2O in the search for a new modality of treatment. T-24 showed a marked reduction in cells at both low and high concentrations of D2O. DU-145 showed mild proliferation in the beginning and became cytostatic in the later stages at low concentrations of D2O, but at a high concentration, the number of cells DU-145 was constantly reduced. A-498 showed constant reduction at both low and high concentration less than T-24. Morphologically, some of the cells showed condensation of chromatic material around the periphery of the nucleus and increased vacuolization of the cytoplasm suggesting apoptosis. And, other cells showed haziness and irregularity of the Outline of the cell which interruption indicates necrosis. We concluded that there is the cytotoxicity mediated with the concentrations of D2O in urological cancer in which induces by both apoptosis and necrosis.
- Uedaira H, Chem. Soc. Jpn., 47(3), 219 (1994)
- Sood SK, Kveton OK, Fusion Technol., 8, 2478 (1985)
- Paek S, Ahn DH, Kim KR, Chung H, J. Ind. Eng. Chem., 8(1), 12 (2002)
- Vasdev S, Sampson CA, Liepins A, J. Hypertens, 8(2), 185 (1990)
- Fischer A, Protoplasma, 26, 51 (1936)
- Choe S, Jung IH, J. Ind. Eng. Chem., 8(4), 297 (2002)
- Takeda H, Nio Y, Omori H, Uegaki K, Hirahara N, Sasaki S, Tamura K, Ohtani H, Anticancer Drugs, 9(8), 715 (1998)
- Altermatt HJ, Gebbers JO, Arnold W, Laissue JA, Laryngol Rhinol Otol, 66(4), 191 (1987)
- Kushner DJ, Baker A, Dunstall TG, Can. J. Physiol Pharm., 77, 79 (1999)
- Uemura T, Moritake K, Akiyama Y, Kimura Y, Shingu T, Yamasaki T, J. Neurosurg., 96, 900 (2002)
- Adams WH, Adams DG, J. Pharm. Exp. Ther., 244, 633 (1988)
- Omori H, Nio Y, Takeda H, Tamura K, Gan Kagaku Ryoho, 23, 1665 (1996)
- Altermatt HJ, Gebbers JO, Laissue JA, Cancer 1, 62(3), 462 (1988)
- Finkel AJ, Czajka DM, Katz JJ, Cancer Chemother Rep., 50, 641 (1966)
- Altermatt HJ, Gebbers JO, Arnold W, Laissue JA, Laryngol Rhinol Otol, 66, 191 (1987)
- Canete M, Villanueva A, Dominguez V, Polo S, Juarranz A, Stockert JC, Int. J. Oncol., 13, 497 (1998)
- Davies S, Spanel P, Smith D, Physiol. Meas, 22, 651 (2001)
- Kovar DA, LEwis M, Karczmar GS, J. Magn. Reson Imaging, 8, 1126 (1998)
- Mickey DD, Stone KR, Wunderli H, Mickey GH, Vollmer RT, Paulson DF, Cancer Res., 37, 4049 (1977)
- Brandau S, Bohle A, Eur. Urol., 39, 491 (2001)
- Kountouras J, Boura P, Lygidakis NJ, Hepatogastroenterology, 47, 1291 (2000)
- Okada F, Kawaguchi T, Habelhah H, Kobayashi T, Tazawa H, Takeichi N, Kitagawa T, Hosokawa M, Lab. Invest., 80, 1617 (2000)
- Hino O, Majima S, Kobayashi T, Honda S, Momose S, Kikuchi Y, Mitani H, Mutat Res., 477, 155 (2001)
- Prout GR, Koontz WW, Coombs LJ, Hawkins IR, Friedell GH, J. Urol., 130, 677 (1983)
- Richie JP, Urol. Clin. North Am., 19, 521 (1992)
- Matsushima H, Kawabe K, Fujime M, Kitamura T, Homma Y, Kishi H, Kawamura T, Umeda T, Ohishi Y, Murai M, Kawai T, Yoshida H, Fukuda T, Oncol Rep., 9, 283 (2002)
- Ueda K, Sakagami H, Ohtaguro K, Masui Y, Eur. Urol., 21, 250 (1992)
- Au JL, Badalament RA, Wientjes MG, Young DC, Warner JA, Venema PL, Pollifrone DL, Harbrecht JD, Chin JL, Lerner SP, Miles BJ, J. Natl Cancer Inst., 93, 597 (2001)
- Hurle R, Manzetti A, Losa A, Micheli E, Ranieri A, Chinaglia D, Lembo A, Urol. Int., 61, 220 (1998)
- Hirao Y, Okajima E, Ohara S, Ozono S, Hiramatsu T, Yoshida K, Yamada K, Aoyama H, Hashimoto M, Watanabe S, Cancer Chemother Pharmacol., 20, S85 (1987)
- Hisazumi H, Uchibayashi T, Naito K, Misaki T, Miyazaki K, J. Urol., 114, 394 (1975)
- Solsona E, Iborra I, Ricos JV, Monros JL, Dumont R, Casanova J, Calabuig C, Eur. Urol., 19, 93 (1991)
- Ilett KF, Ong RT, Batty KT, Taylor JD, Br. J. Urol., 65, 478 (1990)
- Nomata K, Noguchi M, Kanetake H, Tsuda N, Hayashi M, Yamashita S, Sakuragi T, Kusaba Y, Shindo K, Cancer Chemother Pharmacol., 50, 266 (2002)
- Imamoglu Ma, Bakirtas H, Yigitbasi O, Ersoy H, Sertcelik AN, Arch. Esp. Urol., 54, 1147 (2001)
- Badalament Ra, Farah RN, Semin Surg Oncol., 13, 335 (1997)
- Colleen S, Ek A, Hellsten S, Lindholm CE, Scand. J. Urol. Nephrol., 14, 43 (1980)
- Said MT, Abomelha Ms, Orkubi SA, Saudi Med. J., 23, 1458 (2002)
- Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE, J. Urol., 169, 96 (2003)
- Stavropoulos NE, Hastazeris K, Filiadis I, Mihailidis I, Ioachim E, Liamis Z, Kalomiris P, Scand. J. Urol. Nephrol., 36, 218 (2002)
- Shiau AL, Lin CY, Tzai TS, Wu CL, Cancer Gene Ther., 8, 73 (2001)
- DenOtter W, Dobrowolski Z, Bugajski A, Papla B, vanderMeijden AP, Koten JW, Boon TA, Siedlar M, Zembala M, J. Urol., 159, 1183 (1998)
- Santoni A, Velotti F, Giuffrida A, Santoni G, Piccoli M, Immunopharmacol. Immunotoxicol., 19, 1 (1997)
- Akaza H, Shimazaki J, Tashiro K, Kotake T, Okajima E, Kagawa S, Machida T, Gan Kagaku Ryoho, 26, 2049 (1999)
- Jurincic-Winkler CD, vonderKammer H, Beuth J, Scheit KH, Klippel KF, Anticancer Res., 16, 2105 (1996)
- Jurincic-Winkler CD, Gallati H, Alvarez-Mon M, Sippel J, Carballido J, Klippel KF, Eur. Urol., 28, 334 (1995)
- Menke JJ, Heins JR, Annu. Pharmacother, 34, 479 (2000)
- Llopis M, Moreno J, Botella R, Algado M, Acta Urol. Belg, 61, 21 (1993)
- Drago PC, Badalament RA, Lucas J, Drago JR, J. Urol., 142, 1071 (1989)
- Ricos Torrent JV, Fuentes FM, Juan II, Ramon-Borja JC, Monros Lliso JL, CerveraDeval J, Narbon ES, Arch Esp. Urol., 41, 891 (1988)
- Davies S, Smith SD, Physiol. Meas, 22, 651 (2001)
- Kovar DA, Lewis M, Karczmar GS, J. Magn. Reson Imaging, 8, 1126 (1998)